Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 7, 2015, Pages 396-405

  Nayak, S ^a   Lee, D ^a   Patel Hett, S ^a   Pittman, D D ^a   Martin, S W ^a   Heatherington, A C ^a   Vicini, P ^a   Hua, F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; BIOASSAY; BLOOD CLOTTING; CONTROLLED STUDY; DOSE RESPONSE; HEMOPHILIA A; HUMAN; IN VITRO STUDY; LAG TIME; PARTIAL THROMBOPLASTIN TIME; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBIN GENERATION ASSAY; TREATMENT RESPONSE;

EID: 84937946852     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.50     Document Type: Article

References (39)

1. Rand, M.D., Lock, J.B., van't Veer, C., Gaffney, D.P. & Mann, K.G. Blood clotting in minimally altered whole blood. Blood 88, 3432-3445 (1996).
2. Versteeg, H.H., Heemskerk, J.W., Levi, M. & Reitsma, P.H. New fundamentals in hemostasis. Physiol. Rev. 93, 327-358 (2013).
3. Mannucci, P.M. & Tuddenham, E.G. The hemophilias - from royal genes to gene therapy. N. Engl. J. Med. 344, 1773-1779 (2001).
4. Poort, S.R., Michiels, J.J., Reitsma, P.H. & Bertina, R.M. Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder. Thromb. Haemost. 72, 819-824 (1994).
5. Chiu, H.C., Whitaker, E. & Colman, R.W. Heterogeneity of human factor V deficiency. Evidence for the existence of antigen-positive variants. J. Clin. Invest. 72, 493-503 (1983).
6. Bolton-Maggs, P.H. The rare inherited coagulation disorders. Pediatr. Blood Cancer 60(suppl. 1), S37-40 (2013).
7. Mannucci, P.M., Duga, S. & Peyvandi, F. Recessively inherited coagulation disorders. Blood 104, 1243-1252 (2004).
8. Beresford, C.H. Antithrombin III deficiency. Blood Rev. 2, 239-250 (1988).
9. Bertina, R.M. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64-67 (1994).
10. Gandrille, S. et al. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thromb. Haemost. Thromb. Haemost. 77, 1201-1214 (1997).
11. Reitsma, P.H. Protein C deficiency: from gene defects to disease. Thromb. Haemost. 78, 344-350 (1997).
12. Bray, G. et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 83, 2428-2435 (1994).
13. Kim, H.C. et al. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 79, 568-575 (1992).
14. Hay, C., Negrier, C. & Ludlam, C. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb. Haemost. 78, 1463-1467 (1997).
15. Key, N. et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb. Haemost. 80, 912-918 (1998).
16. Leissinger, C. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 5, 25-32 (1999).
17. Buller, H.R. et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 112, 2242-2247 (2008).
18. Eriksson, B.I. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370, 949-956 (2007).
19. Gulati, A., Faed, J.M., Isbister, G.K. & Duffull, S.B. Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin. Pharm. Res. 29, 225-235 (2012).
20. Gulati, A., Isbister, G.K. & Duffull, S.B. Effect of Australian elapid venoms on blood coagulation: Australian Snakebite Project (ASP-17). Toxicon 61, 94-104 (2013).
21. Dargaud, Y., Lienhart, A. & Negrier, C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 116, 5734-5737 (2010).
22. Young, G. et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 121, 1944-1950 (2013).
23. Kogan, A.E., Kardakov, D.V. & Khanin, M.A. Analysis of the activated partial thromboplastin time test using mathematical modeling. Thromb. Res. 101, 299-310 (2001).
24. Luan, D., Szlam, F., Tanaka, K.A., Barie, P.S. & Varner, J.D. Ensembles of uncertain mathematical models can identify network response to therapeutic interventions. Mol. Biosyst. 6, 2272-2286 (2010).
25. Luan, D., Zai, M.C. & Varner, J.D. Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput. Biol. 3, e142 (2007).
26. Hockin, M.F., Jones, K.C., Everse, S.J. & Mann, K.G. A model for the stoichiometric regulation of blood coagulation. J. Biol. Chem. 277, 18322-18333 (2002).
27. Kim, H.K. Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay. BioMed Res. Int. 2013 (2013).
28. Wajima, T., Isbister, G.K. & Duffull, S.B. A comprehensive model for the humoral coagulation network in humans. Clin. Pharmacol. Ther. 86, 290-298 (2009).
29. Chatterjee, M.S., Denney, W.S., Jing, H. & Diamond, S.L. Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood. PLoS Comput. Biol. 6, 9 (2010).
30. Lusher, J.M., Arkin, S., Abildgaard, C.F. & Schwartz, R.S. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A - safety, efficacy, and development of inhibitors. N. Engl. J. Med. 328, 453-459 (1993).
31. Nilsson, I., Berntorp, E., Löfqvist, T. & Pettersson, H. Twenty five years' experience of prophylactic treatment in severe haemophilia A and B. J. Intern. Med. 232, 25-32 (1992).
32. Roberts, H.R., Monroe, D.M. & White, G.C. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 104, 3858-3864 (2004).
33. Agersø, H. et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur. J. Pharm. Sci. 56, 65-69 (2014).
34. Berntorp, E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 15, 3-10 (2009).
35. Dieri, R.A. et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb. Haemost. 88, 576-582 (2002).
36. Kamal, A.H., Tefferi, A. & Pruthi, R.K. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin. Proc. 82, 864-873 (2007).
37. Sørensen, B. & Ingerslev, J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J. Thromb. Haemost. 2, 102-110 (2004).
38. Xu, Z., Chen, N., Kamocka, M.M., Rosen, E.D. & Alber, M. A multiscale model of thrombus development. J. R. Soc. Interface 5, 705-722 (2008).
39. Mann, K.G. Thrombin generation in hemorrhage control and vascular occlusion. Circulation 124, 225-235 (2011).